血清睾酮水平和前列腺癌病理分级及术后病理升级的相关性研究

高原; 邹青松; 毛师魁; 蒿魁元; 夏术阶; 韩邦旻

doi:10.13201/j.issn.1001-1420.2015.10.012

血清睾酮水平和前列腺癌病理分级及术后病理升级的相关性研究

- 上海交通大学附属第一人民医院泌尿外科(上海, 200080)

详细信息

通讯作者: 韩邦旻,E-mail:hanbm@163.com

中图分类号: R737.25

收稿日期: 2015-02-27

Association between low serum testosterone and prostate cancer grade or Gleason Score upgrading

- Department of Urology, First People's Hospital of Shanghai Jiao Tong University, Shanghai, 200080, China

More Information

Corresponding author: HAN Bangmin, E-mail: hanbm@163.com

Received Date: 27 February 2015

摘要

摘要: 目的:探讨行前列腺癌根治术患者血清睾酮水平与其病理分级的关系,以及与根治术后病理升级的相关关系。方法:回顾性研究2013年1月~2014年12月期间于我中心行腹腔镜下前列腺癌根治术的135例患者,收集患者年龄、体质指数(BMI)、前列腺特异性抗原(PSA)、血清睾酮水平及合并伴随疾病等资料,记录患者穿刺病理Gleason评分及根治病理Gleason评分。结果:低睾酮(<300 ng/dl)组的穿刺病理Gleason评分明显高于正常睾酮(≥ 300 ng/dl)组(P=0.02),低睾酮组的根治病理Gleason评分同样也明显高于正常睾酮组(P<0.01)。低睾酮组有20例(45.5%)出现病理升级,而在正常睾酮组有25例(27.5%)出现病理升级,低睾酮组发生根治术后病理升级明显多于正常睾酮组(P=0.04)。结论:临床上较低的睾酮浓度往往预示着更高级别前列腺癌并且同样预示着更易出现前列腺癌根治术后的病理升级,在治疗方式的选择上应当予以重视。
- 前列腺癌 /
- 低睾酮浓度 /
- 病理升级
Abstract: Objective:To investigate the association between serum testosterone and biopsy or pathological Gleason Score (GS), and to assess the relationship between testosterone and GS upgrading after radical prostatectomy.Method:We retrospectively assessed 135 patients who were diagnosed as prostate cancer (PC) by biopsy and treated with laparoscopic radical prostatectomy (LRP) from January 2013 to December 2014 in our medical center. Age, BMI, PSA, total testosterone and comorbidities of patients were measured. Biopsy GS and pathological GS were collected.Result:Low serum testosterone was associated with a higher biopsy GS (P=0.02) and also a higher pathological GS (P<0.01). Meanwhile, a low serum testosterone predicted a higher possibility of GS upgrading after prostatectomy (P=0.04).Conclusion:Low serum testosterone predicts a higher biopsy GS, pathological GS and a higher possibility of GS upgrading after prostatectomy. We should pay attention to it when choosing therapies.
- prostate cancer /
- low serum testosterone /
- Gleason Score upgrading

HTML全文

参考文献(11)

[1]	Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1):9-29.
[2]	毕新刚, 韩仁强, 周金意, 等. 2009年中国前列腺癌发病和死亡分析[J]. 中国肿瘤, 2013, 22(6):417-422.
[3]	Debes J D, Tindall D J. The role of androgens and the androgen receptor in prostate cancer[J]. Cancer Lett, 2002, 187(1-2):1-7.
[4]	Antonarakis E S, Armstrong A J. Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer[J]. Prostate Cancer Prostatic Dis, 2011, 14(3):206-218.
[5]	Botto H, Neuzillet Y, Lebret T, et al. High incidence of predominant Gleason pattern 4 localized prostate cancer is associated with low serum testosterone[J]. J Urol, 2011, 186(4):1400-1405.
[6]	Xylinas E, Ploussard G, Durand X, et al. Low pretreatment total testosterone (< 3 ng/ml) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer[J]. BJU Int, 2011, 107(9):1400-1403.
[7]	Dong F, Jones J S, Stephenson A J, et al. Prostate cancer volume at biopsy predicts clinically significant upgrading[J]. J Urol, 2008, 179(3):896-900.
[8]	Hong S K, Han B K, Lee S T, et al. Prediction of Gleason score upgrading in low-risk prostate cancers diagnosed via multi (> or=12)-core prostate biopsy[J]. World J Urol, 2009, 27(2):271-276.
[9]	Heidenreich A, Bastian P J, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1:screening, diagnosis, and local treatment with curative intent-update 2013[J]. Eur Urol, 2014, 65(1):124-137.
[10]	Müntener M, Epstein J I, Hernandez D J, et al. Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy[J]. Eur Urol, 2008, 53(4):767-776.
[11]	Sooriakumaran P, Srivastava A, Christos P, et al. Predictive models for worsening prognosis in potential candidates for active surveillance of presumed low-risk prostate cancer[J]. Int Urol Nephrol, 2012, 44(2):459-470.